Verastem, Inc. (VSTM) Release: The Potential of Targeting Cancer Stem Cells Through FAK Inhibition In Mesothelioma Reported In American Association for Cancer Research’s Cancer Discovery
6/24/2014 10:18:22 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced publication of an article titled “FAK Inhibitor Kills Mesothelioma Cells” in Cancer Discovery, a medical journal published by the American Association for Cancer Research (AACR). The commentary references preclinical scientific data on targeting mesothelioma cancer stem cells through inhibition of focal adhesion kinase (FAK) that was recently published in Science Translational Medicine (Vol. 6, Issue 237, p.237ra68).
Help employers find you! Check out all the jobs and post your resume.
comments powered by